Skip to main content
  • AACR Journals
    • Blood Cancer Discovery
    • Cancer Discovery
    • Cancer Epidemiology, Biomarkers & Prevention
    • Cancer Immunology Research
    • Cancer Prevention Research
    • Cancer Research
    • Clinical Cancer Research
    • Molecular Cancer Research
    • Molecular Cancer Therapeutics

AACR logo

  • Register
  • Log in
  • My Cart
Advertisement

Main menu

  • Home
  • About
    • The Journal
    • AACR Journals
    • Subscriptions
    • Permissions and Reprints
  • Articles
    • OnlineFirst
    • Current Issue
    • Past Issues
    • Meeting Abstracts
    • Collections
      • COVID-19 & Cancer Resource Center
      • Focus on Radiation Oncology
      • Novel Combinations
      • Reviews
      • Editors' Picks
      • "Best of" Collection
  • First Disclosures
  • For Authors
    • Information for Authors
    • Author Services
    • Best of: Author Profiles
    • Submit
  • Alerts
    • Table of Contents
    • Editors' Picks
    • OnlineFirst
    • Citation
    • Author/Keyword
    • RSS Feeds
    • My Alert Summary & Preferences
  • News
    • Cancer Discovery News
  • COVID-19
  • Webinars
  • Search More

    Advanced Search

  • AACR Journals
    • Blood Cancer Discovery
    • Cancer Discovery
    • Cancer Epidemiology, Biomarkers & Prevention
    • Cancer Immunology Research
    • Cancer Prevention Research
    • Cancer Research
    • Clinical Cancer Research
    • Molecular Cancer Research
    • Molecular Cancer Therapeutics

User menu

  • Register
  • Log in
  • My Cart

Search

  • Advanced search
Molecular Cancer Therapeutics
Molecular Cancer Therapeutics
  • Home
  • About
    • The Journal
    • AACR Journals
    • Subscriptions
    • Permissions and Reprints
  • Articles
    • OnlineFirst
    • Current Issue
    • Past Issues
    • Meeting Abstracts
    • Collections
      • COVID-19 & Cancer Resource Center
      • Focus on Radiation Oncology
      • Novel Combinations
      • Reviews
      • Editors' Picks
      • "Best of" Collection
  • First Disclosures
  • For Authors
    • Information for Authors
    • Author Services
    • Best of: Author Profiles
    • Submit
  • Alerts
    • Table of Contents
    • Editors' Picks
    • OnlineFirst
    • Citation
    • Author/Keyword
    • RSS Feeds
    • My Alert Summary & Preferences
  • News
    • Cancer Discovery News
  • COVID-19
  • Webinars
  • Search More

    Advanced Search

Article

Chemopotentiation of Temozolomide, Irinotecan, and Cisplatin Activity by CEP-6800, a Poly(ADP-Ribose) Polymerase Inhibitor

Sheila J. Miknyoczki, Susan Jones-Bolin, Sonya Pritchard, Kathryn Hunter, Hugh Zhao, Weihua Wan, Mark Ator, Ronald Bihovsky, Robert Hudkins, Sankar Chatterjee, Andres Klein-Szanto, Craig Dionne and Bruce Ruggeri
Sheila J. Miknyoczki
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Susan Jones-Bolin
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Sonya Pritchard
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Kathryn Hunter
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Hugh Zhao
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Weihua Wan
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Mark Ator
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Ronald Bihovsky
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Robert Hudkins
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Sankar Chatterjee
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Andres Klein-Szanto
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Craig Dionne
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Bruce Ruggeri
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
DOI:  Published April 2003
  • Article
  • Figures & Data
  • Info & Metrics
  • PDF
Loading

Online Impact

Statistics from Altmetric.com

ARTICLE USAGE

ARTICLE USAGE: April 2003 to April 2021

AbstractFull-text HTMLPDF
Total452864404122

Cited By

Article Information

Volume 2, Issue 4, pp. 371-382

PubMed 
12700281

Published By 
American Association for Cancer Research
Print ISSN 
1535-7163
Online ISSN 
1538-8514
History 
  • February 3, 2003
  • November 14, 2002
  • January 28, 2003
  • Published first April 1, 2003.

Copyright & Usage 
Molecular Cancer Therapeutics

Author Information

  1. Sheila J. Miknyoczki1,
  2. Susan Jones-Bolin,
  3. Sonya Pritchard,
  4. Kathryn Hunter,
  5. Hugh Zhao,
  6. Weihua Wan,
  7. Mark Ator,
  8. Ronald Bihovsky,
  9. Robert Hudkins,
  10. Sankar Chatterjee,
  11. Andres Klein-Szanto2,
  12. Craig Dionne and
  13. Bruce Ruggeri
  1. Cephalon, Inc., West Chester, Pennsylvania 19380
  1. To whom requests for reprints should be addressed, at Cephalon, Inc., 145 Brandywine Parkway, West Chester, PA 19380. Phone: (610) 738-6509; Fax: (610) 738-6643
View Full Text
PreviousNext
Back to top
Molecular Cancer Therapeutics: 2 (4)
April 2003
Volume 2, Issue 4
  • Table of Contents
  • About the Cover

Sign up for alerts

View this article with LENS

Open full page PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for sharing this Molecular Cancer Therapeutics article.

NOTE: We request your email address only to inform the recipient that it was you who recommended this article, and that it is not junk mail. We do not retain these email addresses.

Enter multiple addresses on separate lines or separate them with commas.
Chemopotentiation of Temozolomide, Irinotecan, and Cisplatin Activity by CEP-6800, a Poly(ADP-Ribose) Polymerase Inhibitor
(Your Name) has forwarded a page to you from Molecular Cancer Therapeutics
(Your Name) thought you would be interested in this article in Molecular Cancer Therapeutics.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Chemopotentiation of Temozolomide, Irinotecan, and Cisplatin Activity by CEP-6800, a Poly(ADP-Ribose) Polymerase Inhibitor
Sheila J. Miknyoczki, Susan Jones-Bolin, Sonya Pritchard, Kathryn Hunter, Hugh Zhao, Weihua Wan, Mark Ator, Ronald Bihovsky, Robert Hudkins, Sankar Chatterjee, Andres Klein-Szanto, Craig Dionne and Bruce Ruggeri
Mol Cancer Ther April 1 2003 (2) (4) 371-382;

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Share
Chemopotentiation of Temozolomide, Irinotecan, and Cisplatin Activity by CEP-6800, a Poly(ADP-Ribose) Polymerase Inhibitor
Sheila J. Miknyoczki, Susan Jones-Bolin, Sonya Pritchard, Kathryn Hunter, Hugh Zhao, Weihua Wan, Mark Ator, Ronald Bihovsky, Robert Hudkins, Sankar Chatterjee, Andres Klein-Szanto, Craig Dionne and Bruce Ruggeri
Mol Cancer Ther April 1 2003 (2) (4) 371-382;
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
    • Abstract
    • Introduction
    • Materials and Methods
    • Results
    • Discussion
    • Footnotes
    • References
  • Figures & Data
  • Info & Metrics
  • PDF
Advertisement

Related Articles

Cited By...

More in this TOC Section

  • Prediction of individual response to platinum/paclitaxel combination using novel marker genes in ovarian cancers
  • Low doses of cisplatin or gemcitabine plus Photofrin/photodynamic therapy: Disjointed cell cycle phase-related activity accounts for synergistic outcome in metastatic non–small cell lung cancer cells (H1299)
  • Semisynthetic homoharringtonine induces apoptosis via inhibition of protein synthesis and triggers rapid myeloid cell leukemia-1 down-regulation in myeloid leukemia cells
Show more Article
  • Home
  • Alerts
  • Feedback
  • Privacy Policy
Facebook  Twitter  LinkedIn  YouTube  RSS

Articles

  • Online First
  • Current Issue
  • Past Issues
  • Meeting Abstracts

Info for

  • Authors
  • Subscribers
  • Advertisers
  • Librarians

About MCT

  • About the Journal
  • Editorial Board
  • Permissions
  • Submit a Manuscript
AACR logo

Copyright © 2021 by the American Association for Cancer Research.

Molecular Cancer Therapeutics
eISSN: 1538-8514
ISSN: 1535-7163

Advertisement